Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss
Cybin Inc. Q3 Earnings: Clinical Advances Amid Financial Loss
Cybin Inc. 第三季度收益：財務損失中的臨床進展
The TDR Three Key Takeaways:
TDR 三個關鍵要點：
Positive Clinical Progress: Cybin Inc. has reported significant advancements in its clinical programs, notably achieving a primary efficacy endpoint in its Phase 2 study of CYB003 for treating Major Depressive Disorder (MDD), and demonstrating favorable safety and pharmacokinetic profiles in its dDMT program with CYB004 and SPL028.
Strategic FDA Clearances and IP Expansion: The company has received FDA clearance for its investigational new drug (IND) application for CYB004, allowing it to proceed with a Phase 2a study in Generalized Anxiety Disorder (GAD). Additionally, Cybin has significantly expanded its Intellectual Property (IP) portfolio, emphasizing its commitment to securing its innovations.
Financial Outlook...
積極的臨床進展：Cybin Inc. 報告了其臨床項目取得的重大進展，值得注意的是，其治療重度抑鬱症（MDD）的 CYB003 二期研究達到了主要療效終點，並且其 CYB004 和 SPL0...
登入免費觀看全文
登入/註冊